Electromedical Technologies (EMED)
OTHER OTC:EMED
Want to see EMED full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/ADate:―
No summary available
Positive Factors
Revenue Model
The diverse revenue model with direct sales, leasing, and subscriptions provides multiple income streams, enhancing financial resilience and adaptability to market changes.
Negative Factors
Negative Profitability
The substantial negative profit margin reflects ongoing operational inefficiencies, which could hinder the company's ability to achieve sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Model
The diverse revenue model with direct sales, leasing, and subscriptions provides multiple income streams, enhancing financial resilience and adaptability to market changes.
Read all positive factors
Electromedical Technologies (EMED) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$746.46K
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)2.22
Revenue Growth-93.00%
EPS Growth79.17%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,732,294,200
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.16
Price to Sales (P/S)14.21
P/FCF Ratio-3.92
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue21.62
Enterprise Value/Gross Profit-14.32
Enterprise Value/Ebitda-0.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Electromedical Technologies Business Overview & Revenue Model
Company Description
Electromedical Technologies, Inc., a bioelectronics manufacturing and marketing company, provides medical devices for pain management in the United States. It offers WellnessPro Plus, a bioelectronics therapy prescription device that is used by co...
How the Company Makes Money
Electromedical Technologies generates revenue primarily through the sale of its bioelectronic devices directly to consumers, healthcare providers, and through distribution partnerships. The company's revenue model includes direct sales, leasing op...
Electromedical Technologies Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 41.20K | 588.37K | 1.35M | 1.15M | 907.36K |
| Gross Profit | -62.18K | 381.20K | 1.05M | 888.64K | 708.13K |
| EBITDA | -915.91K | -1.01M | -1.72M | -2.66M | -5.14M |
| Net Income | -1.44M | -1.29M | -2.64M | -3.47M | -8.48M |
Balance Sheet | |||||
| Total Assets | 860.54K | 529.22K | 748.38K | 1.35M | 1.40M |
| Cash, Cash Equivalents and Short-Term Investments | 435.60K | 10.18K | 87.70K | 368.43K | 383.17K |
| Total Debt | 1.24M | 1.57M | 1.70M | 1.98M | 1.57M |
| Total Liabilities | 4.48M | 4.37M | 3.62M | 3.57M | 2.12M |
| Stockholders Equity | -3.62M | -3.84M | -2.87M | -2.22M | -722.50K |
Cash Flow | |||||
| Free Cash Flow | -149.34K | -112.32K | -1.57M | -773.34K | -1.19M |
| Operating Cash Flow | -149.34K | -112.32K | -1.42M | -773.34K | -1.19M |
| Investing Cash Flow | 0.00 | 0.00 | 1.74M | 0.00 | 0.00 |
| Financing Cash Flow | 574.76K | 34.79K | -608.21K | 758.59K | 1.31M |
Electromedical Technologies Peers Comparison
UnderperformOutperform
Sector (51)
EMED
Electromedical Technologies
―
―
―
ERNA
Eterna Therapeutics
0.15
-2.89
-95.00%
NCEL
NewcelX
3.85
-11.95
-75.63%
BJDX
Bluejay Diagnostics
1.92
-5.76
-75.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―